Location History:
- Oostakker, BE (2014 - 2022)
- Zwijnaarde, BE (2022)
Company Filing History:
Years Active: 2014-2024
Title: Mahan Moshir: Innovator in Combination Therapies for Malignancy
Introduction
Mahan Moshir is a notable inventor based in Oostakker, Belgium. He has made significant contributions to the field of medical therapies, particularly in the treatment of malignancies. With a total of seven patents to his name, Moshir's work focuses on innovative combination therapies aimed at addressing complex medical challenges.
Latest Patents
Among his latest patents is the CD70 combination therapy, which relates to innovative treatment methods for malignancies, especially myeloid malignancies such as acute myeloid leukemia (AML). This invention involves combination therapies that may include an antibody molecule binding to CD70 and at least one additional antibody molecule targeting leukemic stem cells. Preferred targets for these therapies include TIM-3, IL1R3/IL1RAP, and CD47. This groundbreaking approach aims to enhance the effectiveness of treatments for patients suffering from these severe conditions.
Career Highlights
Mahan Moshir has worked with prominent companies in the biotechnology sector, including Argenx BV and Argenx N.V. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to the advancement of innovative therapies.
Collaborations
Moshir has collaborated with notable colleagues such as Karen Silence and Peter Ulrichts. These partnerships have played a crucial role in the development of his patented therapies and have fostered a collaborative environment for innovation.
Conclusion
Mahan Moshir stands out as an influential inventor in the realm of combination therapies for malignancies. His innovative approaches and collaborations have the potential to significantly impact the treatment landscape for patients with acute myeloid leukemia and other malignancies.